U.S. Ophthalmic Compounding Pharmacies Market, by Drug (Mitomycin, Amphotericin, Fluconazole, Voriconazole, Tropicamide, Atropine Sulfate, Albumin 5%, Cyclosporine 0.5-2%, Moxifloxacin, Gentamicin, Vancomycin, Amikacin, Tobramycin, Tetracycline, Metronida

U.S. Ophthalmic Compounding Pharmacies Market, by Drug (Mitomycin, Amphotericin, Fluconazole, Voriconazole, Tropicamide, Atropine Sulfate, Albumin 5%, Cyclosporine 0.5-2%, Moxifloxacin, Gentamicin, Vancomycin, Amikacin, Tobramycin, Tetracycline, Metronidazole, Acetylcysteine, Bevacizumab, Tacrolimus, Retinoic Acid, Carosine, Latanoprost, Dorzolamide, Brimonidine, Timolol, and Others), by Formulation (Eye Drops, Ointments, Injections, and Others), by Therapeutic Application (Dry Eyes, Glaucoma, Cataracts, Conjunctivitis, Age-related Macular Degeneration, Uveitis (Eye Inflammation), and Others), and by Pharmacy Type (503A and 503B) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

When a commercially available medicine does not fit the unique needs of an individual patient (human or animal), the drug is compounded by a certified pharmacist. When a patient may be unable to tolerate a commercially available drug, or when the particular formulation required may be unavailable, or the patient may require a treatment that is currently in short supply or has been withdrawn, compounding is carried out. Compounding is defined by the United States Pharmacopeia Convention (USP) as "the preparation, mixing, assembling, altering, packaging, and labelling of a drug, drug-delivery device, or device under a licensed practitioner's prescription, medication order, or initiative in the course of professional practice.
Market Dynamics
The increasing launches of drugs and adoption of inorganic strategies such as collaborations by the key players operating in the market are expected to drive the market growth during the forecast period. For instance, in November 2021, Fagron Sterile Services, a U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA)-registered 503B outsourcing provider of sterile medications, launched its new innovative silicone-free bevacizumab (AVASTIN) injection using Groninger automation technology in collaboration with West Pharmaceutical Services, Inc., a U.S.-based pharmaceutical company. This silicon-free AVASTIN injection has a long shelf life of 150 days and can be administered safely for ophthalmic applications without depositing any unsafe silicon oil droplets into the eye.
Key features of the study:
This report provides an in-depth analysis of the U.S. ophthalmic compounding pharmacies market and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. ophthalmic compounding pharmacies market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Fagron Sterile Services US, New Drug Loft & VLS Pharmacy, Nora Apothecary, Lifecare Pharmacy, Avella Specialty Pharmacy, Triangle Compounding Pharmacy, O’Brien Pharmacy, Tache Pharmacy, Northmark Pharmacy, Edge Pharma, and ImprimisRx
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. ophthalmic compounding pharmacies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. ophthalmic compounding pharmacies market
Detailed Segmentation:
U.S. Ophthalmic Compounding Pharmacies Market, By Drug:
Mitomycin
Amphotericin
Fluconazole
Voriconazole
Tropicamide
Atropine Sulfate
Albumin 5%
Cyclosporine 0.5-2%
Moxifloxacin
Gentamicin
Vancomycin
Amikacin
Tobramycin
Tetracycline
Metronidazole
Acetylcysteine
Bevacizumab
Tacrolimus
Retinoic Acid
Carosine
Latanoprost
Dorzolamide
Brimonidine
Timolol
Others
U.S. Ophthalmic Compounding Pharmacies Market, By Formulation:
Eye Drops
Ointments
Injections
Others
U.S. Ophthalmic Compounding Pharmacies Market, By Therapeutic Application:
Dry Eyes
Glaucoma
Cataracts
Conjunctivitis
Age-related Macular Degeneration
Uveitis (Eye Inflammation)
Others
U.S. Ophthalmic Compounding Pharmacies Market, By Pharmacy Type:
503A
503B
Company Profiles
Fagron Sterile Services US*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
New Drug Loft & VLS Pharmacy
Nora Apothecary
Lifecare Pharmacy
Avella Specialty Pharmacy
Triangle Compounding Pharmacy
O’Brien Pharmacy
Tache Pharmacy
Northmark Pharmacy
Edge Pharma
ImprimisRx
“*” marked represents similar segmentation in other categories in the respective section.